On May 17, 2022, Mirvie, a pioneer in predicting unexpected pregnancy complications, announced it has raised $60 million in a Series B funding round. The financing was led by Decheng Capital with additional funding from funds and accounts managed by BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield as well as a debt facility with Comerica Bank. The round brings Mirvie’s total funding to date to $90 million. Wilson Sonsini Goodrich & Rosati represented Mirvie on the Series B financing and has advised the company since its inception.

The Series B funding will support Mirvie’s continued clinical and commercial development of the proprietary Mirvie RNA platform, which is the first to predict preeclampsia and preterm birth months before they happen by revealing the underlying biology of each pregnancy. The proprietary Mirvie RNA platform combines revolutionary analysis of tens of thousands of RNA messages from the baby, the placenta and the mom, with machine learning. The platform opens a new window into pregnancy health for expecting parents to act and their doctors to intervene before unexpected complications become a crisis.

The Wilson Sonsini team that advised Mirvie on the transaction included:

Corporate
Ken Clark
Becki DeGraw
Ben Miller

IP (Patents and Innovations)
Vern Norviel
Ali Alemozafar
Dawson Wong

For more information, please see Mirvie’s press release or the coverage in Forbes.